Clinical trialNCT03705169TerminatedPhase 1Interventional

Pharmacokinetics and Safety of SAR441236

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment52HIV-1-infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of SAR441236, a tri-specific broadly neutralizing antibody against the human immunodeficiency virus (HIV).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Athe Tsibris, MD, MS
Brigham and Women's Hospital, Harvard Medical School
Study Chair
clinicaltrials.gov ↗
Daniel R. Kuritzkes, MD
Brigham and Women's Hospital Therapeutics CRS, Harvard Medical School
Study Chair
clinicaltrials.gov ↗
Pablo Tebas, MD
Penn Therapeutics CRS
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Alabama Crs
Birmingham, Alabama, United States
Ucla Care Center Crs
Los Angeles, California, United States
Ucsd Antiviral Research Center Crs
San Diego, California, United States
Ucsf Hiv/aids Crs
San Francisco, California, United States
University of Colorado Hospital Crs
Aurora, Colorado, United States
Northwestern University Crs
Chicago, Illinois, United States
Rush University Crs
Chicago, Illinois, United States
Brigham and Women'S Hospital Therapeutics Clinical Research Site (bwh Tcrs) Crs
Boston, Massachusetts, United States
Massachusetts General Hospital Crs (mgh Crs)
Boston, Massachusetts, United States
Washington University Therapeutics (wt) Crs
St Louis, Missouri, United States
New Jersey Medical School Clinical Research Center Crs
Newark, New Jersey, United States
Weill Cornell Chelsea Crs
New York, New York, United States
Weill Cornell Uptown Crs
New York, New York, United States
University of Rochester Adult Hiv Therapeutic Strategies Network Crs
Rochester, New York, United States
Chapel Hill Crs
Chapel Hill, North Carolina, United States
Cincinnati Clinical Research Site
Cincinnati, Ohio, United States
Case Clinical Research Site
Cleveland, Ohio, United States
Ohio State University Crs
Columbus, Ohio, United States
Penn Therapeutics, Crs
Philadelphia, Pennsylvania, United States
University of Pittsburgh Crs
Pittsburgh, Pennsylvania, United States
the Miriam Hospital Clinical Research Site (tmh Crs) Crs
Providence, Rhode Island, United States
Vanderbilt Therapeutics (vt) Crs
Nashville, Tennessee, United States
University of Washington Positive Research Crs
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboSAR441236

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 May 2019
Primary completion: 4 Apr 2022
Completion: 4 Apr 2022
Last update posted: 12 Jan 2024
Registered enrollment: 52
Registry id: NCT03705169

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.